Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effects of reformulation: improved therapeutic index.

Literature DB >> 18947511

The effects of reformulation: improved therapeutic index.

Scott MacDiarmid¹, Bobby W Sandage, Bimal K Malhotra.

Abstract

Antimuscarinic agents are the treatment of choice for overactive bladder syndrome. Due to the development of novel delivery systems, extended-release formulations of oxybutynin, tolterodine, and trospium chloride are now available. In addition to the convenience of once-daily dosing, the new formulations of these commonly prescribed agents have improved their therapeutic index, striking a better balance between efficacy and tolerability.

Entities: Chemical Disease

Mesh：

Substances：

Year: 2008 PMID： 18947511 DOI： 10.1007/s11934-008-0080-6

Source DB: PubMed Journal: Curr Urol Rep ISSN： 1527-2737 Impact factor: 3.092

35 in total

Review 1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal: Urology Date: 2003-01 Impact factor: 2.649

Review 2. Transdermal delivery of drugs for urologic applications: basic principles and applications.

Authors: Victor W Nitti; Steven Sanders; David R Staskin; Roger R Dmochowski; Peter K Sand; Scott MacDiarmid; Howard I Maibach
Journal: Urology Date: 2006-04 Impact factor: 2.649

Review 3. Clinical pharmacokinetics of trospium chloride.

Authors: Oxana Doroshyenko; Alexander Jetter; Karl P Odenthal; Uwe Fuhr
Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447

Review 4. Medical treatment and medical side effects in urinary incontinence in the elderly.

Authors: J W Thüroff; E Chartier-Kastler; J Corcus; J Humke; U Jonas; H Palmtag; E A Tanagho
Journal: World J Urol Date: 1998 Impact factor: 4.226

5. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

Authors: K Waldeck; B Larsson; K E Andersson
Journal: J Urol Date: 1997-03 Impact factor: 7.450

6. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors: P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal: Urology Date: 2001-03 Impact factor: 2.649

Review 7. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.

Authors: L Nilvebrant; B Hallén; G Larsson
Journal: Life Sci Date: 1997 Impact factor: 5.037

Review 8. Interventions for helping patients to follow prescriptions for medications.

Authors: R B Haynes; H McDonald; A X Garg; P Montague
Journal: Cochrane Database Syst Rev Date: 2002

9. Multicenter phase III trial studying trospium chloride in patients with overactive bladder.

Authors: Delbert Rudy; Kevin Cline; Richard Harris; Kenneth Goldberg; Roger Dmochowski
Journal: Urology Date: 2006-02 Impact factor: 2.649

10. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

Authors: David Staskin; Peter Sand; Norman Zinner; Roger Dmochowski
Journal: J Urol Date: 2007-07-16 Impact factor: 7.450

6 in total

The effects of reformulation: improved therapeutic index.

Review 1. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Review 2. Transdermal delivery of drugs for urologic applications: basic principles and applications.

Review 3. Clinical pharmacokinetics of trospium chloride.

Review 4. Medical treatment and medical side effects in urinary incontinence in the elderly.

5. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

6. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Review 7. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.

Review 8. Interventions for helping patients to follow prescriptions for medications.

9. Multicenter phase III trial studying trospium chloride in patients with overactive bladder.

10. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

1. Defining efficacy in the treatment of overactive bladder syndrome.

2. The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy.

3. The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.

4. Will the evolution of overactive bladder delivery systems increase patient compliance?

5. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.

6. Recent advances in management of bladder overactivity.